Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial

Author:

Liu Tianshu1,Qin Yanru2,Li Jin34,Xu Ruihua5,Xu Jianming6,Yang Shujun7,Qin Shukui8,Bai Yuxian9,Wu Changping10,Mao Yixiang11,Wu Haiyan11,Ge Yilin12,Shen Lin13ORCID

Affiliation:

1. Department of Oncology; Zhongshan Hospital, Fudan University; Shanghai 200032 P. R. China

2. Department of Clinical Oncology; The First Affiliated Hospital, Zhengzhou University; Zhengzhou 450052 Henan P. R. China

3. Department of Medical Oncology; Fudan University Shanghai Cancer Center; Shanghai 200032 P. R. China

4. Department of Oncology; Tongji University Eastern Hospital; Shanghai 200120 P. R. China

5. Department of Medical Oncology; Sun Yat-Sen University Cancer Center; Guangzhou 510060 Guangdong P. R. China

6. Department of Oncology; 307th Hospital of PLA, Academy of Military Medical Sciences; Beijing 100071 P. R. China

7. Department of Medical Oncology; Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital; Zhengzhou 450008 Henan P. R. China

8. Department of Oncology; People's Liberation Army (PLA) Cancer Center, 81st Hospital of PLA; Nanjing 210002 Jiangsu P. R. China

9. Medical Department; Harbin Medical University Cancer Hospital; Harbin 150081 Heilongjiang P. R. China

10. Department of Oncology; First People's Hospital of Changzhou; Changzhou 213003 Jiangsu P. R. China

11. Roche (China) Holding Co., Ltd.; Shanghai 201203 P. R. China

12. Medical Division; Shanghai Roche Pharmaceuticals Ltd.; Shanghai 201203 P. R. China

13. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology; Peking University Cancer Hospital and Institute; #52 Fucheng Road, Haidian District Beijing 100142 P. R. China

Funder

Shanghai Roche Pharmaceuticals Ltd., China

F. Hoffmann-La Roche

Shanghai Roche Pharmaceuticals Ltd.

Publisher

Wiley

Subject

Cancer Research,Oncology

Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3